news

Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatment

Provides furthered momentum for OXU-003 development programme OXFORD, England, Oct. 12, 2020 Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (U.S. FDA) for OXU-003, the Company’s proprietary drug in development for the treatment of retinoblastoma. …

Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatment Read More »

Oxular Limited Appoints Dr. Rafiq Hasan as Non-Executive Director

Oxular Limited Appoints Dr. Rafiq Hasan as Non-Executive Director OXFORD, UK, 5 October 2020 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has appointed Dr. Rafiq Hasan as a Non-Executive Director of the Company. Dr. Hasan gained his medical degree in London and has pursued a highly successful career in …

Oxular Limited Appoints Dr. Rafiq Hasan as Non-Executive Director Read More »

Oxular appoints Prof. Marc de Smet as Chief Medical Officer

Prof. Marc de Smet joins Oxular Prof. de Smet is a retinal surgeon with more than 30 years of experience in ophthalmic drug andmedical device development 1 February 2019 – Oxular Limited, the Oxford-based retinal therapeutics company, today announces that it has appointed Prof. Marc de Smet to the position of Chief Medical Officer. Marc will …

Oxular appoints Prof. Marc de Smet as Chief Medical Officer Read More »

OBN Awards 2016 –Winners Recognised at Industry Leading Event

Abingdon, UK, 7 October 2016 – OBN Ltd, the membership organisation supporting the UK’s innovative life sciences companies, are delighted to announce the winners of the prestigious OBN Awards 2016 that were presented last night in front of a sold-out audience of over 250 leaders from Biotech, Medtech and Investment companies at the Town Hall …

OBN Awards 2016 –Winners Recognised at Industry Leading Event Read More »

Precision Ocular Ltd Completes £15.5 million Series A Financing

V-Bio Ventures joins investment syndicate Completes oversubscribed £15.5 million Series A financing round Accelerates development of additional product candidates Investors include Imperial Innovations, Consort Medical plc, NeoMed, V-Bio Ventures and Hovione Scientia Ltd Tuesday, 19 July 2016 – Precision Ocular, the Oxford-based retinal therapeutics company, today announces that V-Bio Ventures joins the Company’s successful Series …

Precision Ocular Ltd Completes £15.5 million Series A Financing Read More »

Innovations leads £13.5m funding round in Precision Ocular

22 February 2016 – Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) has led a £13.5 million investment round in Precision Ocular Ltd (Precision Ocular), a London-based retinal therapeutics company. Innovations has committed £6.9 million to the round alongside other investors, including Consort Medical plc, a leading global single source pharma services drug and …

Innovations leads £13.5m funding round in Precision Ocular Read More »

Scroll to Top